Novartis talks up potential blockbusters
This article was originally published in Scrip
With its sweeping revamp now complete, Novartis says it is putting the bulk of its efforts into expanding underlying growth generated from innovative new drugs, many of which have big blockbuster potential. Two are new breakthrough drugs - Cosentyx (secukinumab) and Entresto (sacubitril/valsartan) – while another is the former GlaxoSmithKline oncology asset Promacta (eltrombopag olamine).
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.